In VivoBiopharma merger and acquisition value for the first quarter of 2025 reached $38.4bn from 41 transactions, 22 of which had disclosed values. Making up almost 38% of that total was Johnson & Johnso
ScripWhile the world’s pharma industry has increasingly connected with Chinese-developed me-too or fast-follower novel drugs over the past few years, AstraZeneca, which already has more than three decades
ScripAstraZeneca already considers China one of its most important markets and is increasing its focus there, announcing a $2.5bn research and development investment in Beijing along with three partnership
ScripScrip regularly covers business development and deal making in the biopharmaceutical industry. Asia Deal Watch is supported by deal intelligence from Biomedtracker. Deal Brings AstraZeneca Greater C